Investigating how the androgen receptor influences prostate cancer growth and treatment.
Official title: Growth suppressive and oncogenic transcriptional programs controlled by the androgen receptor in prostate cancer
Funded at Weill Medical Coll of Cornell Univ · NIH-11055791 · Data updated 2026-11-12
This study is looking at how a protein called the androgen receptor can change from helping normal prostate cells grow to fueling prostate cancer, and it aims to find ways to turn its cancer-fighting abilities back on to help stop the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 1, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $564,543 |
| NIH project number | 1R01CA297829-01 |
| Project ID | NIH-11055791 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those whose disease has become resistant to current treatments.
✕Less likely to help
Patients with early-stage prostate cancer or those without androgen receptor involvement may not benefit from this research.
What this research studies
This research focuses on the role of the androgen receptor (AR) in prostate cancer, particularly how it can switch from promoting normal cell growth to driving cancer progression. The team aims to identify the factors that mediate this switch and explore whether the growth-suppressive functions of AR can be reactivated to inhibit cancer. By utilizing advanced biological models and novel systems to manipulate AR activity, the research seeks to enhance our understanding of AR's role in both normal prostate function and cancer development.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that reactivate the growth-suppressive functions of the androgen receptor, potentially improving outcomes for patients with advanced prostate cancer.
How similar studies have gone: Previous research has shown promising results in targeting the androgen receptor in prostate cancer, indicating that this approach has potential for success.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Barbieri, Christopher E — Weill Medical Coll of Cornell Univ
- Study coordinator: Barbieri, Christopher E
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.